Published in final edited form as:

Org Lett. 2010 February 19; 12(4): 756. doi:10.1021/ol902820z.

Chirality Holds the Key for Potent Inhibition of the Botulinum Neurotoxin Serotype A Protease

G. Neil Stowe^a, Peter Šilhár^a, Mark S. Hixon^b, Nicholas R. Silvaggi^c, Karen N. Allen^{c,*}, Scott T. Moe^d, Alan R. Jacobson^{d,*}, Joseph T. Barbieri^e, and Kim D. Janda^{a,*}

^aDepartments of Chemistry and Immunology, The Skaggs Institute for Chemical Biology and Worm Institute of Research and Medicine (WIRM), The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037

^bTakeda San Diego, Inc., 10410 Science Center Drive, San Diego, CA 92121

^cDepartment of Chemistry, Boston University, Boston, MA 02215

^dAbsolute Science, Inc., PO Box 382366, Cambridge, MA 02238

^eDepartments of Microbiology and Molecular Genetics, Medical College of Wisconsin, 8701 Watertown Plank Road, Milwaukee, WI 53226

Abstract

Botulinum neurotoxin serotype A (BoNT/A) is the most toxic protein known to man, and also a bioterrorism agent. As defined by our previous research targeting the etiological agent responsible for BoNT/A intoxication, a protease, we now report on the asymmetric synthesis of four new BoNT/A inhibitors; the most potent of this series is roughly twofold more active than the best small molecule inhibitor currently known.

The seven serotypes (A–G) of botulinum neurotoxins (BoNTs) are proteins produced by bacteria of the genus *Clostridium*.¹ BoNTs are synthesized as ~150-kDa proteins consisting of a 100-kDa heavy chain (HC) and a 50-kDa light chain (LC) linked by disulfide bonds.² The HC is responsible for translocation and binding, while the LC is a zinc-dependent endopeptidase that cleaves soluble *N*-ethylmaleimide-sensitive fusion proteins (SNARE) located at nerve endings.³ Cleavage of SNARE proteins by the BoNT LC leads to flaccid

drkallen@bu.edu, arj@absolutescience.com, kdjanda@scripps.edu.

Supporting Information Available Experimental synthetic procedures and NMR and HRMS data for all previously unreported compounds. This information is available free of charge via the Internet at <http://pubs.acs.org>.

paralysis and subsequent death due to inhibition of the release of acetylcholine from synaptic terminals.⁴

Current treatment for BoNT intoxication employs an antitoxin to sequester the toxin followed by removal of the complex from the body. However, this treatment option is dependent upon prompt diagnosis of intoxication, and must be administered rapidly before the toxin can enter the cell.⁵ The antitoxin also suffers from the risk of allergic reaction,⁶ long term effects of unknown origin⁷ and insufficient available quantities for treatment of a large scale attack.⁸

BoNT serotype A (BoNT/A) is considered to be the most deadly BoNT serotype based on the following: first, and most importantly, BoNT/A has an extremely long duration of action, i.e. weeks to months. Second, there is no antidote for BoNT/A intoxication, with severe intoxication cases requiring mechanical ventilation due to respiratory paralysis.⁹ Third, BoNT/A, together with serotype B, is responsible for ~1000 cases of human BoNT poisoning per year.¹ Finally, BoNT/A has a high potential for bioterrorism use due to its extreme toxicity and ease of dissemination through the food or water supply. Thus, the inhibition of BoNT/A LC is an attractive target for non-peptidic small molecules that can target the enzyme within an intoxicated cell.

Previous research from one of our laboratories screened a diverse library of small molecules and discovered several inhibitors of BoNT/A, with *trans*-cinnamic hydroxamate **1** being our initial lead (Figure 1). Hydroxamate **2** stemmed from structure activity studies, and is one of the most potent inhibitors known, having a K_i value of 300 ± 12 nM.¹⁰ From these studies several lessons were learned including: (1) all structures required the hydroxamate functionality, a monoanionic bidentate chelator of zinc that has been previously used for the inhibition of metalloproteinases,¹¹ (2) the need for a *para*-halogenated phenyl ring¹² and (3) an *ortho*, *para*-dihalogenated ring was superior to *para*-substitution alone¹⁰ (Figure 1). Indeed, x-ray crystallographic analysis of the bound inhibitors revealed hydroxyl coordination of the hydroxamate to the Zn (II) ion in the active site in addition to phenyl ring interaction with a hydrophobic portion of the enzyme.² Addition of the *ortho* chlorine substituent created an additional favorable interaction with an active site arginine, making for the most potent inhibitor reported to date.²

While our initial research has been critical to lending credence that small non-peptidic molecules can be tailored to the BoNT/A protease, it is readily apparent that more potent inhibitors will be required if a therapeutic is the final goal. As such, we sought to synthesize a series of molecules containing additional chemical diversity for potential interaction(s) with the enzyme active site. We envisioned the preparation of hydroxy ethyl hydroxamates (*R*), (*S*)-**4–5**, which would not only extend within polar space of the enzyme's combining site but would also explore the importance of molecular chirality and its impact on enzyme inhibition.

We viewed these structures as rational choices based on active site molecular modeling wherein a key goal was to displace a nascent water molecule within the enzyme active site, which based on previous protease inhibitors targeting active site water molecules could improve K_i up to 100 fold.¹³ To access such structures required an asymmetric synthetic strategy that would construct both enantiomers of the final hydroxamate products from a single, readily available, starting material (Scheme 1). Herein, we report the successful asymmetric synthesis and inhibitory evaluation of hydroxamates (*R*), (*S*)-**4–5** with BoNT/A protease.

Our envisioned hydroxamate synthesis involved ring opening of the corresponding lactones (*R*), (*S*)-**23–24**, which could be independently synthesized from acid/esters **15–16** via chemoselective lactonization.¹⁴ Acid/ester **15** was previously synthesized in high enantiomeric excess (>98%) and yield (85%) by chymotrypsin mediated enantioselective hydrolysis of diester **13**,¹⁵ and we reasoned that the previously unreported hydrolysis of diester **14** using a

similar chemoenzymatic approach could be successful due to the similar nature of the two structures. We planned to synthesize diesters **13–14** from readily available starting materials as shown in Scheme 2.

Thus, our synthesis of diesters **13–14** started with the synthesis of alkenes **9–10** using the aqueous Wittig reaction of methyl bromoacetate with the appropriate aldehyde¹⁶ followed by Michael-type addition of dimethyl malonate to yield triesters **11–12** in good yield.^{12a} Selective triester decarboxylation¹⁷ yielded diesters **13–14**, the substrates for enzymatic hydrolysis. Diester **13** was hydrolyzed with chymotrypsin to give (*R*) acid/ester **15** with high enantioselectivity and chemical yield. Hydrolysis of *ortho*, *para*-dichloro diester **14** using chymotrypsin also proceeded with high enantioselectivity (>99%) and respectable yield (45%) to give (*R*) acid/ester **16**. The enantioselectivity and absolute stereochemistry of these hydrolytic enzymatic resolutions was determined by acid derivitization using (*R*) and (*S*)-1-(1-naphthyl)-ethylamine followed by comparison of the difference in chemical shift of the diastereomeric methoxy ester protons **19–20** and **21–22** according to the procedure of Hoyer et al. (Scheme 2).¹⁸

With acids **15–16** in hand we sought to prepare both enantiomers of lactones **23–24** via chemoselective lactonization.¹² Thus, ester reduction with LiBH₄ followed by cyclization under acidic conditions yielded (*S*) lactones **23–24**. Conversely, (*R*) lactones **23–24** were prepared by carboxylic acid reduction with BH₃·DMS followed by lactonization under acidic conditions. The lactones were then smoothly converted to hydroxamates (*R*), (*S*)-**4–5** employing hydroxylamine under basic conditions¹¹ (Scheme 3).

All hydroxamates were screened for activity against BoNT/A using our LC/MS based assay that employs a truncated version of SNAP-25, the SNARE protein cleaved by the BoNT/A LC.¹⁹ Our results clearly show the importance of chirality; in both cases the (*R*) hydroxamate IC₅₀ was less than the (*S*) hydroxamate. The K_i of (*R*) *para*-chloro and *ortho*, *para*-dichloro hydroxamates (*R*)-**4** and (*R*)-**5** was determined to be 1.7 ± 0.3 and 0.16 ± 0.02 μM, respectively, (Table 1) with inhibition being competitive in nature (data not shown). Importantly, hydroxamate (*R*)-**5** is roughly two-fold more effective than the best small molecule non-peptidic BoNT/A inhibitor known. We did not determine K_i values for hydroxamates (*S*)-**4–5** since they were inferior inhibitors as shown by IC₅₀ values.

In summary, a concise asymmetric synthesis of four new inhibitors of the highly toxic BoNT/A LC has been devised. As discovered previously, the *ortho*, *para*-dichloro hydroxamates are more potent inhibitors than the simple *para*-chloro hydroxamates. We have also clearly shown that control of stereochemistry is crucial for optimum inhibition. Finally, we note that a crystal structure of hydroxamate (*R*)-**4** within the BoNT/A active site has been solved,²⁰ supporting our hypothesis that the hydroxyethyl moiety of (*R*)-**4–5** replaces an active site water molecule. Additional research using a combination of crystallography, synthesis and kinetic analysis is envisioned to discover more potent inhibitors of this unique metalloprotease, and will be reported in due course.

Supplementary Material

Refer to Web version on PubMed Central for supplementary material.

Acknowledgments

This project has been funded with federal funds from the National Institute of Allergy and Infectious Diseases, National Institutes of Health and the Department of Health and Human Services under contract numbers N01-AI30050 and AI080671. JTB wishes to acknowledge membership within and support from the Region V 'Great Lakes' RCE (NIH award 1-U54-AI-057153).

References

1. Roxas-Duncan V, Enyedy I, Montgomery VA, Eccard VS, Carrington MA, Lai H, Gul N, Yang DCH, Smith LA. *Antimicrob. Agent. Chemother* 2009;53:3478–3486.
2. Silvaggi NR, Boldt GE, Hixon MS, Kennedy JP, Tzipori S, Janda KD, Allen KN. *Chem. Biol* 2007;14:533–542. [PubMed: 17524984]
3. Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, De. Camilli P, Sudhof TC, Niemann H, Jahn R. *Nature* 1993;365:160–163. [PubMed: 8103915]
4. Hambleton P. *J. Neurol* 1992;239:16–20. [PubMed: 1311751]
5. Capkova K, Salzameda NT, Janda KD. *Toxicon* 2009;54:575–582. [PubMed: 19327377]
6. (a) Black RE, Gunn RA. *Am. J. Med* 1980;69:567–570. [PubMed: 7191633] (b) Villar RG, Elliott SP, Davenport KM. *Infect. Dis. Clin. North AM* 2006;20:313–327. [PubMed: 16762741]
8. Arnon SS, Schechter R, Inglesby TH, Henderson DA, Bartlett JG, Ascher MS, Eitzen E, Fine AD, Hauer J. *JAMA* 2001;285:1050–1079.
9. Hicks RP, Hartell MG, Nichols DA, Bhattacharjee AK, Von Hamont JE, Skillman DR. *Curr. Med. Chem* 2005;12:667–690. [PubMed: 15790305]
10. Boldt GE, Kennedy JP, Janda KD. *Org. Lett* 2006;8:1729–1732. [PubMed: 16597152]
11. (a) Skiles JW, Gonnella NC, Jeng AY. *Curr. Med. Chem* 2004;22:2911–2977. [PubMed: 15544483] (b) Grant S, Easley C, Kirkpatrick P. *Nat. Rev. Drug Discov* 2007;6:21–22. [PubMed: 17269160]
12. Capkova K, Yoneda Y, Dickerson TJ, Janda KD. *Bioorg. Med. Chem. Lett* 2007;17:6463–6466. [PubMed: 17951059]
13. (a) Silvaggi NR, Wilson D, Tzipori S, Allen KN. *Biochemistry* 2008;47:5736–5745. [PubMed: 18457419] (b) Fu Z, Chen S, Baldwin MR, Boldt GE, Crawford A, Janda KD, Barbieri JT, Kim JJ. *Biochemistry* 2006;45:8903–8911. [PubMed: 16846233] (c) Rich DH, Sun ETO. *J. Med. Chem* 1980;23:27–33. [PubMed: 6767029]
14. (a) Huang FC, Lee LFH, Mittal RSD, Ravikumar PR, Chan JA, Sih CJ, Caspi E, Eck CR. *J. Am. Chem. Soc* 1975;97:4144–4149. [PubMed: 1159219] (b) Yu MS, Lantos I, Peng Z, Yu J, Cacchio T. *Tetrahedron Lett* 2000;41:5647–5651.
15. (a) Chenevert R, Desjardins M. *Can. J. Chem* 1994;72:2312–2317. (b) Chen L, Zaks A, Chackalamannil S, Dugar S. *J. Org. Chem* 1996;61:8342–8343.
16. El-Batta A, Jiang C, Zhao W, Anness R, Cooksy AL, Bergdahl M. *J. Org. Chem* 2007;72:5244–5259. [PubMed: 17559278]
17. Krapcho AP. *Synthesis* 1982:805–808.
18. (a) Hoye TR, Koltun D. *J. Am. Chem. Soc* 1998;120:4638–4643. (b) Hoye TR, Hamad AS, Koltun DO, Tennakoon MA. *Tetrahedon Lett* 2000;41:2289–2293.
19. Capkova K, Hixon MS, McAllister LA, Janda KD. *Chem. Commun* 2008:3525–3527.
20. Silvaggi NR, Allen KN. The crystal structure and additional kinetic findings will be published elsewhere.

Figure 1.
Structure and IC_{50} Values of Previously Identified BoNT/A Inhibitors.

Scheme 1.A) Structures of Hydroxamates (*R*), (*S*)-**4-5**; B) Retrosynthetic Analysis

Scheme 2.

Synthesis of Acids **15**–**16** and derivitization to determine ee and stereochemistry.

Scheme 3.
 Synthesis of Hydroxamate Enantiomers (*R*), (*S*)-4–5.

Table 1IC₅₀ and K_i Values for Hydroxamates (*R*), (*S*)-**4-5**.

Compound	IC ₅₀ (μM)	K _i (μM)
(<i>S</i>)- 4	36	n.d.
(<i>R</i>)- 4	8	1.7 ± 0.3
(<i>S</i>)- 5	21	n.d.
(<i>R</i>)- 5	1	0.16 ± 0.02

Assays were conducted at 22.5°C, pH 7.4 in 40 mM HEPES buffer at 10 μM inhibitor concentration, 0.075 nM enzyme (BoNT/A) concentration using SNAP-25 (66-mer) substrate. An entry of n.d. denotes value was not determined.